REGENXBIO (NASDAQ:RGNX) Share Price Crosses Above 50-Day Moving Average – Time to Sell?

Posted by Stanley Muller on Nov 11th, 2026

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $7.77 and traded as high as $8.23. REGENXBIO shares last traded at $8.07, with a volume of 2,174,000 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on RGNX shares. Robert W. Baird lowered their target price on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, August 25th. Wall Street Zen lowered REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright restated a “buy” rating on shares of REGENXBIO in a report on Monday, September 28th. Barclays downgraded REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday, August 7th. Finally, UBS Group reiterated a “positive” rating on shares of REGENXBIO in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $23.18.

View Our Latest Report on RGNX

REGENXBIO Stock Up 10.1%

The company has a market cap of $560.04 million, a price-to-earnings ratio of -2.64 and a beta of 1.24. The firm has a 50 day moving average price of $7.72 and a two-hundred day moving average price of $8.96.

REGENXBIO (NASDAQ:RGNX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.67. The firm had revenue of $9.16 million during the quarter, compared to analyst estimates of $10.89 million. REGENXBIO had a negative net margin of 113.85% and a negative return on equity of 203.98%. On average, equities analysts expect that REGENXBIO Inc. will post -3.01 earnings per share for the current year.

Institutional Trading of REGENXBIO

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of REGENXBIO in the 2nd quarter worth about $76,641,000. Bank of America Corp DE acquired a new stake in REGENXBIO during the second quarter worth approximately $6,212,000. Corient Private Wealth LP acquired a new stake in REGENXBIO during the second quarter worth approximately $2,608,000. Deutsche Bank AG bought a new stake in REGENXBIO in the second quarter worth approximately $2,490,000. Finally, Walleye Capital LLC bought a new stake in REGENXBIO in the second quarter worth approximately $2,441,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

(Get Free Report)

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients’ cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.